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Morbidity and Mortality After D2 Gastrectomy for Gastric
Cancer: Results of the Italian Gastric Cancer Study Group
Prospective Multicenter Surgical Study
By Maurizio Degiuli, Mitsuru Sasako, Antonio Ponti, Tito Soldati, Francesco Danese, and Fabio Calvo
Purpose: To investigate whether pancreas preserva-
tion together with a strict quality-control system could
ameliorate the outcome of D2 resections for gastric
cancer in Western patients.
Patients and Methods: Italian patients with poten-
tially curable proven adenocarcinoma of the stomach
were registered from nine general and/or university
hospitals in the area of Turin, Northern Italy. The study
was performed according to the guidelines of the Japa-
nese Research Society for Gastric Cancer (JRSGC). A
strict quality-control system was guaranteed by a super-
vising surgeon of the reference center, who had stayed
at the National Cancer Center Hospital, Tokyo, to learn
the standard D2 gastrectomy. The standard procedure
entailed removal of the level 1 and 2 lymph nodes.
During total gastrectomy, the pancreas was preserved
according to the Maruyama technique.
JAPANESE INVESTIGATORS have been reporting for
years successful survival data with slight morbidity and
low mortality rates after extended (D2) dissection for gastric
cancer.' These radical procedures include removal of the
level 2 nodes (N2) in addition to the perigastric nodes (NI). 2
There has always been a reluctance by Western surgeons
to adopt these more extensive procedures, due to the fear of
increasing early morbidity and mortality rates. In fact, two
recent European randomized controlled trials demonstrated
that D2 gastrectomies are followed by higher morbidity and
mortality rates than DI resections and that these disadvan-
tages may prove to nullify any survival benefit.3 ,4
The routine adoption of distant pancreatectomy and
splenectomy during total gastrectomy has been advocated as
one of the reasons for the significant increase of morbidity
and mortality after the more extensive procedures. 4 The
Italian Gastric Cancer Study Group (GCSG) was set up to
determine whether pancreas preservation during total gastrec-
tomy, together with a strict-quality control system, would
ameliorate the early results of D2 resections and therefore
prolong the survival of patients. We chose to conduct, at
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Results: Between May 1994 and December 1996, 191
eligible patients were entered onto the study. The mean
number of lymph nodes removed was 39. The overall
morbidity rate was 20.9%. Surgical complications were
observed in 16.70/% of patients. Reoperation was necessary
in six patients and was always successful. The overall
hospital mortality rate was 3.10/%; it was higher after total
gastrectomy (7.46%) than after distal gastrectomy (0.8%).
The average length of hospital stay was 17 days.
Conclusion: Given that postoperative morbidity and
mortality rates are favorably comparable with those
reported after the Western standard gastrectomy, the
more extensive Japanese procedure with pancreas pres-
ervation can be regarded as a safe radical treatment of
gastric cancer for selected Western patients treated in
experienced centers.
Clin Oncol 16:1490-1493. c 1998 by American Soci-
ety of Clinical Oncology.
first, a prospective one-arm multicenter trial with a strict
quality-control protocol and patient selection criteria similar
to those adopted in the recently published randomized trials. 3,4
We now report our data on postoperative morbidity and
mortality.
PATIENTS AND METHODS
Registration
Patients eligible for the trial were to have proven adenocarcinoma of
the stomach that was potentially curable. Patients who required
emergency procedures, had a coexisting cancer, or were older than 80
years of age were not enrolled. Also excluded were patients with severe
cardiorespiratory dysfunctions that precluded more extensive dissec-
tions.
The study was directed from a central office at the reference center
(Department of Oncology, Division of Surgery, Turin, Italy). Informed
consent was obtained from the patients in accordance with the ethical
principles adopted by each participating hospital. Data on recruitment,
surgical procedures, histopathologic findings, postoperative course, and
patient follow-up evaluation were collected by a surgeon at each
institution and posted to a registry at the central office.
Assessment of Cancer Curability
Preoperative staging was performed to exclude clinical evidence of
distant metastasis. At laparotomy, patients were to have no evidence of
peritoneal and/or liver metastasis (P0, HO); no involvement of the
esophagus, cardia, or duodenum; and no metastasis in paraaortic (N4)
and retropancreatic nodes (N3) at biopsy or in frozen sections.
Treatment
The study was performed according to the guidelines of the Japanese
Research Society for Gastric Cancer (JRSGC). 2,5 The standard proce-
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dure entailed removal of the level 1 and 2 nodes. Nodes of the
hepatoduodenal ligament were also removed following the technique
performed at the National Cancer Center Hospital, Tokyo.6 During total
gastrectomy, the pancreas was preserved according to the Maruyama
technique, unless it was suspected to be involved by the tumor.7
Quality Control
The Italian GCSG was set up in March 1994; eight university and/or
general hospitals from Turin, Northern Italy, participated. In June 1995,
a ninth hospital center joined the group. Each center had two surgeons
attend all of the operations. In total, 18 surgeons participated in the trial.
Before the beginning of the trial, M.D., a surgeon from the reference
center, stayed at the National Cancer Center Hospital, Tokyo, to learn
the D2 dissection from a specialist Japanese surgeon (M. Sasako). He
was also given various didactic videos and papers taped and edited by
M.S. and/or his colleagues. M.D. became the supervising surgeon of the
trial. After this period, and before the trial was run, several meetings
were organized among participating centers to explain the terminology,
debate the proper indications, and demonstrate the technique. At least
one of the two surgeons of each participating center attended the first 10
procedures in this trial, which were performed at the reference center.
Afterwards, M.D. attended the first three operations performed at each
center.
Statistical Aspects
Sample size calculations were performed with the intent to achieve a
proportion of hospital deaths (5%) and of postoperative complications
(25%) similar to those usually obtained with standard D1 resections. 3,4,8
The target for enrollment was then set to approximately 200 patients,
based on the desired level of precision in estimating the parameters of
interest for the study (hospital mortality: 95% confidence interval [CI],
2.5% to 9.0%; postoperative complications: 95% CI, 19.0% to 31.5%).
CIs for percentages are based on exact binomial probabilities. The x2
test was used to assess differences in proportions.
RESULTS
A total of 297 patients were referred to the participating
centers between May 1994 and December 1996. Of these,
191 who fulfilled the eligibility criteria were entered onto
the study. One hundred six patients were found to be
ineligible, mostly because their disease was more extended
than that required for the trial. The characteristics of eligible
patients are listed in Table 1.
Removal of Lymph Nodes
Overall, the mean number of nodes removed was 39,
ranging from 22 to 93. No center removed less than an
average of 25 nodes per patient (Table 2). The median
number of positive nodes, in node-positive patients, was 10,
with a range of one to 54. Table 3 lists the extent of lymph
node involvement in the study population.
Postoperative Hospital Morbidity
Postoperative complications are listed in Table 4. The
overall morbidity rate was 20.9% (95% CI, 15.4% to
27.4%). Surgical complications accounted for 16.7%. Among
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Table 1. Site of Tumor, Type of Gastrectomy, and Pathologic Stage
No. of
Variable Patients %
Eligible patients
Site of tumor
Lower third
Middle third
Upper third
Diffuse (> 2/3 of stomach)
Stump (previous resection for peptic disease)
Type of resection
Distal
Total
Japanese group staging
I (EGC)
III
IV
Curativity
Absolutely curative
Relatively curative, noncurative
191 100
116
52
13
6
4
60.8
27.2
6.8
3.1
2.1
124 64.9
67 35.1
68
30
68
25
35.6
15.7
35.6
13.1
125 65.4
66 34.6
Abbreviation: EGL, early gastric cancer.
these, anastomotic leakage was observed in 14 patients
(7.1%). Two instances of ischemic liver necrosis consequent
to the ligature of the left hepatic artery in the lesser omentum
were registered. Eight patients (4.1%) had major nonsurgical
complications, two of which were fatal. Six patients had a second
operation, mostly because of an abdominal infection due to
anastomotic leakage. All of these reoperations were successful.
Postoperative Hospital Mortality
The overall hospital mortality was six of 191 patients
(3.1%; 95% CI, 1.2% to 6.7%) (Table 5). Three deaths
occurred due to intraabdominal infectious complications. Of
the six deaths, five were observed in patients who underwent
total gastrectomy and splenectomy, four of whom had
disease classified as tumor-node-metastasis (TNM) stage IV
because of the involvement of the hepatoduodenal ligament
nodes. The hospital mortality rate was 7.46% after total
gastrectomy, while it was 0.8% after distal resection
(P < .05).
Table 2. Number of Lymph Nodes Removed at Each Participating Center
No. of Lymph
Center Nodes Removed Range
Calderini 37 23-89
Calvo 44 24-73
Capussotti 33 22-53
Dellepiane 31 23-68
Fronda 41 22-84
Garavoglia 25 24-39
Locatelli 40 22-70
Mello 50 24-93
Morino 39 26-58
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Table 3. Lymph Node Involvement
Overall (N = 191) EGC (N = 68)
Involvement No. % No. %
pNO 78 35.4 54 79.4
pN+ 113 64.6 14 20.6
pN1 41 21.5 8 11.8
pN2 56 29.3 5 7.3
pN3* 16 8.4 1 1.5
*Involvement of location no. 12 lymph nodes (lymph nodes of the hepatoduo-
denal ligament).
Postoperative Hospital Stay
The mean length of hospital stay was 17
61).
DISCUSSION
Over the years, Japanese investigators ha
cial survival effects with low morbidity ar
less than 3% after extensive dissections fo
The main reasons for the successful Jap
technical skills and strict respect to the tre
actually, in Japan, D2 resection is a con
ordinary general hospitals.
In Western centers, extensive procedures
because of the fear of increasing earl)
mortality.10 Although low morbidity and mr
also been reported in the West (mostly
studies),11,12 two main recent prospective r
found that D2 resections are associated
morbidity and mortality rate than Dl proc
analysis of these trials has demonstrated th
Table 4. Types of Complications
Surgical Complications
Anastomotic leakage (esophagojejunal)
Anastomotic leakage (gastrojejunal)
Duodenal stump leakage
Colonic perforation
Acute pancreatitis and gallbladder perforation
Pancreatic fistula
Anastomotic bleeding
Ischemic liver necrosis*
Anastomotic edema
Laparocele
Intestinal occlusion
Peritonitis
Jejunal torsion
Total non-surgical complications
Cardiac
Pulmonary
Thromboembolic
Total
Total complications
DEGIULI ET AL
Table 5. Postoperative Mortality: 6 Patients (3.1%)
Age of
Patients Type of
(years) Stage Goastrecomy Cause of Death
68 IlIA Total Liver necrosis and abdominal infection
69 IA Distal Myocardial infarction
74 IV Total Esophagojejunal leakage
89 IV Total Duodenal stump leakage
69 IV Total Pleuric empyema
70 IV Total Stroke
morbidity in the D2 arm is largely due to distal pancreatic
days (range, 7 to resection and splenectomy, which have been performed
routinely during total gastrectomy. 4 The unfavorable postop-
erative outcome reported may prove to nullify any survival
benefit of extensive procedures in Medical Research Council
Ive shown benefi- (MRC) and Dutch patients.
Id mortality rates Our study was designed to test the feasibility and safeness
ir gastric cancer.9  of the extensive procedure if performed with a strict
anese results are quality-control system and if total gastrectomy with D2
atment schedule; dissection is performed without distal pancreatectomy, un-
nmon practice in less pancreas involvement is suspected. The lymph nodes
along the splenic artery (no. 11) were removed following the
are not common technique described by Maruyama et al.
7
morbidity and We have previously reported our interim analysis of
mortality rates have morbidity and mortality in the first 118 patients treated with
in retrospective D2 dissection; hospital mortality and postoperative morbid-
randomized trials ity rates were 2.5% and 20.3%, respectively. 13 Actually, the
d with a higher overall postoperative morbidity rate is 20.9%; the rate of
:edures.3, 4 Subset anastomotic and duodenal stump leakage is 7.1%, while the
at the increase of rate of nonsurgical complications is only 4.1%. The overall
postoperative mortality rate is 3.1%. Of six deaths, five
occurred in patients submitted to total gastrectomy and
No. of splenectomy; of these five patients, four had stage IV disease
Patients % (due to the involvement of location no. 12 lymph nodes).
7 3.6 Our final results show that hospital mortality and postopera-
3 1.5 tive morbidity after D2 dissection with pancreas preserva-
4 2.0 tion can be kept at levels comparable to those achieved after1 0.5
1 0.5 standard D1 dissection in Western series8,10 and in the
1 0.5 control arms of the recently published randomized trials.3,4
2 1.0 The rates of anastomotic leakages were similar in all of these
2 1.0 trials, whereas intraabdominal infection and pancreatic
3 1.5 leakage rates, as well as the nonsurgical morbidity rate, were1 0.5
2 1.0 lower in the present study. The mortality rate after anasto-
3 1.5 motic leakage is approximately 15%, which is close to that
1 0.5 observed in Japan and lower than that reported by Bonen-
32 16.7 kamp et al.3 The mortality rate was higher after total than
2 1.0 after distal gastrectomy in the present series, although the
5 2.6 pancreas was routinely preserved; this seems to suggest a
1 0.5 further adverse effect of splenectomy on early outcome, as
8 4.1 recently described by various investigators at second World
40 20.9 Congress of the International Gastric Cancer Association, in
Munich, Germany.'4 ,15 On the other hand, the mortality ratei , Germany./4,15 On the other 
hand, the mortality rate
*One patient developed abdominal infection.
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after distal gastrectomy is 0.8, which is close to that reported
by Japanese investigators. These data may prove to support
our study protocol, mostly as regards the quality control.
Patient selection is not likely to be the reason for our low
morbidity and mortality rates. Characteristics of recruited
cases are indeed similar to the study population of the Dutch
and British randomized trials. A further reason for our
sucessful outcome could be the number of patients operated
on at each institution. Apart from the ninth center, which
joined the GCSG a year after the study was started, each
participating center treated at least 15 patients, and five of
them treated more than 25. In every center, each patient was
always treated by the same two operating surgeons, who
attended each operation together. Since the learning curve
has been recently suggested by Parikh et a116 to last for 15 to
25 procedures, each center should consequently have ac-
quired sufficient experience and technical skill. Given that
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postoperative morbidity and mortality are comparable if not
better than those reported after the Western standard tech-
nique,3 ,4,8, 9 the more extensive procedure with preservation
of the pancreas can be regarded as a safe radical treatment of
gastric cancer for Western patients in experienced centers.
Moreover, it can be performed in controlled trials to assess
its efficacy on survival without the adverse effect of an
unfavorable early outcome. We are planning to run a new
randomized controlled three-arm trial to compare the early
outcome and survival of standard D1 gastrectomy with the
more extensive pancreas-preserving D2 procedure with and
without splenectomy.
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